{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:49:14Z","timestamp":1790254154638,"version":"4.1.0"},"reference-count":156,"publisher":"Bioscientifica","issue":"12","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour\u2019s site of origin. Current medical therapy for the treatment of acromegaly and GEP-NET involves the administration of somatostatin analogues that effectively suppress excess hormone secretion. After its discovery in 1979, octreotide became the first synthetic biologically stable somatostatin analogue with a short-acting formulation of octreotide introduced into clinical practice in the late 1980s. Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days. Long-acting release formulations of both octreotide (Sandostatin LAR and Novartis) and lanreotide (Somatuline Autogel, Ipsen), based on microparticle and nanoparticle drug-delivery technologies, respectively, were later developed, which allowed for once-monthly administration and improved convenience. First-generation somatostatin analogues remain one of the cornerstones of medical therapy in the management of pituitary and GEP-NET hormone hypersecretion, with octreotide having the longest established efficacy and safety profile of the somatostatin analogue class. More recently, pasireotide (Signifor), a next-generation multireceptor-targeted somatostatin analogue, has emerged as an alternative therapeutic option for the treatment of acromegaly. This review summarizes the development and clinical success of somatostatin analogues.<\/jats:p>","DOI":"10.1530\/erc-16-0151","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T21:50:18Z","timestamp":1475531418000},"page":"R551-R566","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":88,"title":["Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future"],"prefix":"10.1530","volume":"23","author":[{"given":"Kjell","family":"\u00d6berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W J","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2016110218184898000_23.12.R551.1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1450137"},{"key":"2016110218184898000_23.12.R551.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00760.x"},{"key":"2016110218184898000_23.12.R551.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2104"},{"key":"2016110218184898000_23.12.R551.4","doi-asserted-by":"publisher","DOI":"10.1159\/000201396"},{"key":"2016110218184898000_23.12.R551.5","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ec1261"},{"key":"2016110218184898000_23.12.R551.6","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277936"},{"key":"2016110218184898000_23.12.R551.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1912"},{"key":"2016110218184898000_23.12.R551.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030266"},{"key":"2016110218184898000_23.12.R551.9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01876.x"},{"key":"2016110218184898000_23.12.R551.10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0331"},{"key":"2016110218184898000_23.12.R551.11","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90087-X"},{"key":"2016110218184898000_23.12.R551.12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0310-7"},{"key":"2016110218184898000_23.12.R551.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1563-2571.2000.00106.x"},{"key":"2016110218184898000_23.12.R551.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01710.x"},{"key":"2016110218184898000_23.12.R551.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0669"},{"key":"2016110218184898000_23.12.R551.16","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903379525"},{"key":"2016110218184898000_23.12.R551.17","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"2016110218184898000_23.12.R551.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.179.4068.77"},{"key":"2016110218184898000_23.12.R551.19","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460707"},{"key":"2016110218184898000_23.12.R551.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"2016110218184898000_23.12.R551.21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0315"},{"key":"2016110218184898000_23.12.R551.22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3757"},{"key":"2016110218184898000_23.12.R551.23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.1.99"},{"key":"2016110218184898000_23.12.R551.24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318"},{"key":"2016110218184898000_23.12.R551.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0693-y"},{"key":"2016110218184898000_23.12.R551.26","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.2.270"},{"key":"2016110218184898000_23.12.R551.27","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-007-9062-0"},{"key":"2016110218184898000_23.12.R551.28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1546"},{"key":"2016110218184898000_23.12.R551.29","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0002"},{"key":"2016110218184898000_23.12.R551.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743"},{"key":"2016110218184898000_23.12.R551.31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480"},{"key":"2016110218184898000_23.12.R551.32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0684-z"},{"key":"2016110218184898000_23.12.R551.33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117"},{"key":"2016110218184898000_23.12.R551.34","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100451"},{"key":"2016110218184898000_23.12.R551.35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191"},{"key":"2016110218184898000_23.12.R551.36","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0773"},{"key":"2016110218184898000_23.12.R551.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.1.168"},{"key":"2016110218184898000_23.12.R551.38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/10.suppl_2.S31"},{"key":"2016110218184898000_23.12.R551.39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-9-711"},{"key":"2016110218184898000_23.12.R551.40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02639.x"},{"key":"2016110218184898000_23.12.R551.41","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01191"},{"key":"2016110218184898000_23.12.R551.42","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0282-z"},{"key":"2016110218184898000_23.12.R551.43","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0249"},{"key":"2016110218184898000_23.12.R551.44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0260"},{"key":"2016110218184898000_23.12.R551.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.007"},{"key":"2016110218184898000_23.12.R551.46","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X"},{"key":"2016110218184898000_23.12.R551.47","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01619.x"},{"key":"2016110218184898000_23.12.R551.48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2609"},{"key":"2016110218184898000_23.12.R551.49","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345774"},{"key":"2016110218184898000_23.12.R551.50","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.12.741"},{"key":"2016110218184898000_23.12.R551.51","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0372"},{"key":"2016110218184898000_23.12.R551.52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411"},{"key":"2016110218184898000_23.12.R551.53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn351"},{"key":"2016110218184898000_23.12.R551.54","doi-asserted-by":"publisher","DOI":"10.1210\/er.2000-0001"},{"key":"2016110218184898000_23.12.R551.55","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0267"},{"key":"2016110218184898000_23.12.R551.56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01168.x"},{"key":"2016110218184898000_23.12.R551.57","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2039-y"},{"key":"2016110218184898000_23.12.R551.58","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00986.x"},{"key":"2016110218184898000_23.12.R551.59","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302012000800007"},{"key":"2016110218184898000_23.12.R551.60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly \u2013 2011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocrine Practice"},{"key":"2016110218184898000_23.12.R551.61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700"},{"key":"2016110218184898000_23.12.R551.62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0676"},{"key":"2016110218184898000_23.12.R551.63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-448"},{"key":"2016110218184898000_23.12.R551.64","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-005-5222-2"},{"key":"2016110218184898000_23.12.R551.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.2056"},{"key":"2016110218184898000_23.12.R551.66","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0367"},{"key":"2016110218184898000_23.12.R551.67","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-6-1161"},{"key":"2016110218184898000_23.12.R551.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512193132504"},{"key":"2016110218184898000_23.12.R551.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340408"},{"key":"2016110218184898000_23.12.R551.70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0026-0495(95)90306-2","article-title":"Sandostatin LAR: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients","volume":"44","author":"Lancranjan","year":"1995","journal-title":"Metabolism"},{"key":"2016110218184898000_23.12.R551.71","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0394"},{"key":"2016110218184898000_23.12.R551.72","doi-asserted-by":"publisher","DOI":"10.1159\/000095530"},{"key":"2016110218184898000_23.12.R551.73","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2006.104.6.899"},{"key":"2016110218184898000_23.12.R551.74","first-page":"765","article-title":"Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR","volume":"18","author":"Lundin","year":"1997","journal-title":"American Journal of Neuroradiology"},{"key":"2016110218184898000_23.12.R551.75","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0533-x"},{"key":"2016110218184898000_23.12.R551.76","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0908"},{"key":"2016110218184898000_23.12.R551.77","doi-asserted-by":"crossref","first-page":"e14660","DOI":"10.1200\/jco.2011.29.15_suppl.e14660","article-title":"Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy","volume":"29","author":"Martin-Richard","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"2016110218184898000_23.12.R551.78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060041"},{"key":"2016110218184898000_23.12.R551.79","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0697"},{"key":"2016110218184898000_23.12.R551.80","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2332"},{"key":"2016110218184898000_23.12.R551.81","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0811"},{"key":"2016110218184898000_23.12.R551.82","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363220-00014"},{"key":"2016110218184898000_23.12.R551.83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra062453"},{"key":"2016110218184898000_23.12.R551.84","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2466"},{"key":"2016110218184898000_23.12.R551.85","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4113"},{"key":"2016110218184898000_23.12.R551.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.12.008"},{"key":"2016110218184898000_23.12.R551.87","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00924.x"},{"key":"2016110218184898000_23.12.R551.88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0027"},{"key":"2016110218184898000_23.12.R551.89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2032"},{"key":"2016110218184898000_23.12.R551.90","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.9.2768"},{"key":"2016110218184898000_23.12.R551.91","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01863"},{"key":"2016110218184898000_23.12.R551.92","unstructured":"Novartis Pharmaceuticals 2012 Sandostatin LAR (Octreotide Acetate) Basic Prescribing Information. East Hanover, NJ, USA: Novartis Pharmaceuticals."},{"key":"2016110218184898000_23.12.R551.93","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000167739.56948.a9"},{"key":"2016110218184898000_23.12.R551.94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"2016110218184898000_23.12.R551.95","first-page":"P916","article-title":"Lanreotide-induced bradycardia and supraventricular extrasystoles","volume":"35","author":"Ogmen","year":"2015","journal-title":"Endocrine Abstracts"},{"key":"2016110218184898000_23.12.R551.96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.21.15186"},{"key":"2016110218184898000_23.12.R551.97","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1999.0183"},{"key":"2016110218184898000_23.12.R551.98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"2016110218184898000_23.12.R551.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.015"},{"key":"2016110218184898000_23.12.R551.100","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011408727"},{"key":"2016110218184898000_23.12.R551.101","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01824"},{"key":"2016110218184898000_23.12.R551.102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061523"},{"key":"2016110218184898000_23.12.R551.103","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1986"},{"key":"2016110218184898000_23.12.R551.104","doi-asserted-by":"publisher","DOI":"10.1021\/ja9088023"},{"key":"2016110218184898000_23.12.R551.105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000438903","article-title":"Cardiovascular disease and sleep-disordered breathing in acromegaly","volume":"103","author":"Powlson","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2016110218184898000_23.12.R551.106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03789.x"},{"key":"2016110218184898000_23.12.R551.107","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0738"},{"key":"2016110218184898000_23.12.R551.108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"2016110218184898000_23.12.R551.109","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0106"},{"key":"2016110218184898000_23.12.R551.110","first-page":"429","article-title":"Carcinoid tumors","volume":"74","author":"Robertson","year":"2006","journal-title":"American Family Physician"},{"key":"2016110218184898000_23.12.R551.111","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3484"},{"key":"2016110218184898000_23.12.R551.112","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2559-8"},{"key":"2016110218184898000_23.12.R551.113","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345491"},{"key":"2016110218184898000_23.12.R551.114","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1565"},{"key":"2016110218184898000_23.12.R551.115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"2016110218184898000_23.12.R551.116","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443"},{"key":"2016110218184898000_23.12.R551.117","doi-asserted-by":"publisher","DOI":"10.1016\/S1042-3680(02)00035-9"},{"key":"2016110218184898000_23.12.R551.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.09.006"},{"key":"2016110218184898000_23.12.R551.119","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-11-0224"},{"key":"2016110218184898000_23.12.R551.120","doi-asserted-by":"publisher","DOI":"10.1159\/000080741"},{"key":"2016110218184898000_23.12.R551.121","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02312"},{"key":"2016110218184898000_23.12.R551.122","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-203"},{"key":"2016110218184898000_23.12.R551.123","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01734.x"},{"key":"2016110218184898000_23.12.R551.124","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0033"},{"key":"2016110218184898000_23.12.R551.125","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200106000-00008"},{"key":"2016110218184898000_23.12.R551.126","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0458"},{"key":"2016110218184898000_23.12.R551.127","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03555.x"},{"key":"2016110218184898000_23.12.R551.128","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0896"},{"key":"2016110218184898000_23.12.R551.129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2265.2000.01073.x","article-title":"World Health Organization international histological classification of tumours: histological typing of endocrine tumours: second edition.","volume":"53","author":"Solcia","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"2016110218184898000_23.12.R551.130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0026-0495(96)90088-8","article-title":"Presurgical octreotide: treatment in acromegaly","volume":"45","author":"Stevenaert","year":"1996","journal-title":"Metabolism"},{"key":"2016110218184898000_23.12.R551.131","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0314"},{"key":"2016110218184898000_23.12.R551.132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.1514"},{"key":"2016110218184898000_23.12.R551.133","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3419"},{"key":"2016110218184898000_23.12.R551.134","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0356"},{"key":"2016110218184898000_23.12.R551.135","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0562"},{"key":"2016110218184898000_23.12.R551.136","doi-asserted-by":"publisher","DOI":"10.1016\/S1773-2247(11)50009-7"},{"key":"2016110218184898000_23.12.R551.137","doi-asserted-by":"publisher","DOI":"10.1246\/cl.2012.1090"},{"key":"2016110218184898000_23.12.R551.138","doi-asserted-by":"crossref","unstructured":"Tiberg F Johnsson M Nistor C Joabsson F 2012b Self-assembling lipid formulations. In Long-Acting Injections and Implants, pp 315\u2013334. Eds Wright JC Burgess DJ. New York, NY, USA: Springer.","DOI":"10.1007\/978-1-4614-0554-2_16"},{"key":"2016110218184898000_23.12.R551.139","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12698"},{"key":"2016110218184898000_23.12.R551.140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004203421604"},{"key":"2016110218184898000_23.12.R551.141","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03620.x"},{"key":"2016110218184898000_23.12.R551.142","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#"},{"key":"2016110218184898000_23.12.R551.143","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-004-0466-2"},{"key":"2016110218184898000_23.12.R551.144","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02084.x"},{"key":"2016110218184898000_23.12.R551.145","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03288.x"},{"key":"2016110218184898000_23.12.R551.146","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06844-1"},{"key":"2016110218184898000_23.12.R551.147","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.478"},{"key":"2016110218184898000_23.12.R551.148","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2508"},{"key":"2016110218184898000_23.12.R551.149","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400080073013"},{"key":"2016110218184898000_23.12.R551.150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2151"},{"key":"2016110218184898000_23.12.R551.151","doi-asserted-by":"publisher","DOI":"10.1159\/000095532"},{"key":"2016110218184898000_23.12.R551.152","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"Journal of Endocrinological Investigation"},{"key":"2016110218184898000_23.12.R551.153","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug, Design, Development and Therapy"},{"key":"2016110218184898000_23.12.R551.154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"2016110218184898000_23.12.R551.155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"2016110218184898000_23.12.R551.156","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0434"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/23\/12\/R551.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/23\/12\/R551.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:42Z","timestamp":1784555622000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/23\/12\/R551-R566\/34052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":156,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/erc-16-0151","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}